Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) is expected to release the results from its Phase 2b IMAGINE trial of PBT2 for the treatment of Alzheimer’s disease within the coming month. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) shares after opening at $10.27 moved to $10.66 on last trade day and at the end of the day closed at $10.49. Company price to sales ratio in past twelve months was calculated as 1409.30 and price to cash ratio as 24.16. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) showed a positive weekly performance of 1.55%.
Apricus Biosciences, Inc (NASDAQ:APRI) is reporting for the quarter ending December 31, 2013. The drug company’s consensus earnings per share forecast from the 2 analysts that follow the stock is $-0.06. This value represents a 71.43% increase compared to the same quarter last year. The “days to cover” for this stock exceeds 10 days. Apricus Biosciences Inc (NASDAQ:APRI) shares advanced 6.91% in last trading session and ended the day on $2.63. APRI return on equity ratio is recorded as -545.70% and its return on assets is -190.40%. Apricus Biosciences Inc (NASDAQ:APRI) yearly performance is 3.54%.
Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2013. Pernix Therapeutics Holdings Inc (NASDAQ:PTX) shares moved up 7.74% in last trading session and was closed at $3.76 while trading in range of $3.52 – $3.78 – Pernix Therapeutics Holdings Inc (NASDAQ:PTX) year to date (YTD) performance is 49.21%.
Teva Pharmaceutical Industries Ltd. (ADR) (NYSE:TEVA) announced a significant collaboration between Teva and the United Kingdom (UK) Government’s National Health Service National Institute for Health Research (NIHR) Office for Clinical Research Infrastructure (NOCRI). Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) weekly performance is -1.32%. On last trading day company shares ended up $49.36. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) distance from 50-day simple moving average (SMA50) is 9.15%. Analysts mean target price for the company is $49.30.